Physician profile
Edward Thomas Schaefer
NPI 1114369279
$365.59
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $17.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $94.55 | 2019 | |
| Abbvie INC. | $90.78 | 2019 | |
| Janssen Biotech, INC. | $75.33 | 2019 | |
| Ucb, INC. | $39.06 | 2019 | |
| Amgen INC. | $19.29 | 2019 | |
| Glaxosmithkline, LLC. | $17.78 | 2021 | |
| Boston Scientific Corporation | $15.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.